Immunohistochemical, cytomorphological, and cytogenetic findings in tumor cells in childhood non-Hodgkin lymphoma subtypes.
| Marker . | T-LBL . | PTCL . | ALCL . | pB-LBL . | Burkitt . | DLBCL . | PMLBL . |
|---|---|---|---|---|---|---|---|
| Abbreviations : T-LBL, precursor–T-cell lymphoblastic lymphoma; PTCL, peripheral T-cell lymphoma, unspecified; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large-cell lymphoma; pB-LBL, precursor B-cell lymphoblastic lymphoma; PMLBL, primary mediastinal (thymic) large B-cell lymphoma; NA, not applicable ; +, positive ; +/−, often positive ; −/+, occasionally positive ; −, negative | |||||||
| *and light chain restriction κ or α | |||||||
| †positive only in the rare plasmablastic variant Adapted from Jaffe et al.1 | |||||||
| TdT | + | – | – | + | – | – | – |
| CD19 | – | – | – | + | + | + | + |
| CD20 | – | – | – | +/− | + | + | + |
| CD79a | – | – | – | + | + | + | + |
| Cyμ | – | – | – | −/+ | −/+ | −/+ | – |
| SIg* | – | – | – | – | + | +/− | – |
| Pax5 | – | – | – | + | + | + | + |
| Bcl-6 | – | – | – | – | + | +/− | – |
| CD1a | +/− | – | – | – | – | – | – |
| cμCD3 | + | – | −/+ | – | – | – | – |
| sCD3 | −/+ | +/− | −/+ | – | – | – | – |
| CD4 | −/+ | +/− | −/+ | – | – | – | – |
| CD5 | +/− | +/− | −/+ | – | – | −/+ | – |
| CD7 | +/− | +/− | −/+ | – | – | – | – |
| CD8 | −/+ | −/+ | −/+ | – | – | – | – |
| CD56 | – | −/+ | −/+ | – | – | – | – |
| CD10 | +/− | – | – | +/− | + | +/− | – |
| CD30 | – | −/+ | + | – | – | −/+ | +/− |
| Alk | – | – | 80% + | – | – | −† | – |
| FAB-cytology | L1/L2 | NA | NA | L1/L2 | L3 | NA | NA |
| Cytogenetics | Translocations involving 14q11.252 Few data on T-LBL available so far | t(2;5)(p23;q35) t(1;2)(q25;p23) plus other less frequent translocations involving 2p23 | No data | t(8;14)(q24;q32) t(2;8)(p11;q24) t(8;22)(q24;q11) | |||
| Marker . | T-LBL . | PTCL . | ALCL . | pB-LBL . | Burkitt . | DLBCL . | PMLBL . |
|---|---|---|---|---|---|---|---|
| Abbreviations : T-LBL, precursor–T-cell lymphoblastic lymphoma; PTCL, peripheral T-cell lymphoma, unspecified; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large-cell lymphoma; pB-LBL, precursor B-cell lymphoblastic lymphoma; PMLBL, primary mediastinal (thymic) large B-cell lymphoma; NA, not applicable ; +, positive ; +/−, often positive ; −/+, occasionally positive ; −, negative | |||||||
| *and light chain restriction κ or α | |||||||
| †positive only in the rare plasmablastic variant Adapted from Jaffe et al.1 | |||||||
| TdT | + | – | – | + | – | – | – |
| CD19 | – | – | – | + | + | + | + |
| CD20 | – | – | – | +/− | + | + | + |
| CD79a | – | – | – | + | + | + | + |
| Cyμ | – | – | – | −/+ | −/+ | −/+ | – |
| SIg* | – | – | – | – | + | +/− | – |
| Pax5 | – | – | – | + | + | + | + |
| Bcl-6 | – | – | – | – | + | +/− | – |
| CD1a | +/− | – | – | – | – | – | – |
| cμCD3 | + | – | −/+ | – | – | – | – |
| sCD3 | −/+ | +/− | −/+ | – | – | – | – |
| CD4 | −/+ | +/− | −/+ | – | – | – | – |
| CD5 | +/− | +/− | −/+ | – | – | −/+ | – |
| CD7 | +/− | +/− | −/+ | – | – | – | – |
| CD8 | −/+ | −/+ | −/+ | – | – | – | – |
| CD56 | – | −/+ | −/+ | – | – | – | – |
| CD10 | +/− | – | – | +/− | + | +/− | – |
| CD30 | – | −/+ | + | – | – | −/+ | +/− |
| Alk | – | – | 80% + | – | – | −† | – |
| FAB-cytology | L1/L2 | NA | NA | L1/L2 | L3 | NA | NA |
| Cytogenetics | Translocations involving 14q11.252 Few data on T-LBL available so far | t(2;5)(p23;q35) t(1;2)(q25;p23) plus other less frequent translocations involving 2p23 | No data | t(8;14)(q24;q32) t(2;8)(p11;q24) t(8;22)(q24;q11) | |||